Endothelin as a clinical target in the treatment of systemic hypertension

Cardiology in Review

Volumn 17, Issue 4, 2009, Pages 181-191

  Prasad, Vinoy S ^a   Palaniswamy, Chandrasekar ^b   Frishman, William H ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Blood pressure; Dual angiotensin II endothelin A antagonist; Endothelial dysfunction; Endothelin; ET receptor antagonists; Hypertension

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; AMBRISENTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; AVOSENTAN; BMS 193884; BMS 207940; BOSENTAN; BQ 610; CLAZOSENTAN; CP 170687; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1 [11-21]; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; L 751281; LU 208075; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; PS 433540; RD 46 2005; RO 640612; SITAXSENTAN; TAK 044; TBC 3711; TEZOSENTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 598;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOCRINE EFFECT; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CLINICAL TRIAL; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; FLUSHING; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LIVER TOXICITY; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW; SCLERODERMA; SIDE EFFECT; TISSUE INJURY; VASOCONSTRICTION;

ANTIHYPERTENSIVE AGENTS; ENDOTHELINS; HUMANS; HYPERTENSION; RECEPTORS, ENDOTHELIN;

EID: 68049088897     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181aa8f4a     Document Type: Review

References (139)

1. Hickey KA, Rubanyi GM, Paul RJ, et al. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 1985; 248:C550-C556.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Frishman WH, Kaur S, Singh I, et al. Endothelin as a therapeutic target in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill 2003:527-543.
4. Kloog Y, Ambar I, Sokolovsky M, et al. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988; 242:268-270.
5. Kramer BK, Nishida M, Kelly RA, et al. Endothelins: myocardial actions of a new class of cytokines. Circulation. 1992;85:350-356.
6. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol. 2005; 43:19-29.
7. Bloch KD, Hong CC, Eddy RL, et al. cDNA cloning and chromosomal assignment of the endothelin 2 gene: vasoactive intestinal contractor peptide is rat endothelin 2. Genomics. 1991;10:236-242.
8. Inoue A, Yanagisawa M, Takuwa Y, et al. The human preproendothelin-1 gene. J Biol Chem. 1989;264:14954-14959.
9. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863-2867.
10. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
11. Saida K, Kometani N, Masuda H, et al. Structure of the mouse preproendothelin-3 and phylogentic analysis of the endothelins. J Cardiovasc Pharmacol. 2000;36(suppl 1):S1-S4.
12. Webb DJ, Strachan FE. Clinical experience with endothelin antagonists. Am J Hypertens. 1998;11(4 pt 3):71S-79S.
13. Shimada K, Matsushita Y, Wakabayashi K, et al. Cloning and functional expression of human endothelin converting enzyme cDNA. Biochem Biophys Res Commun. 1995;207:807-812.
14. Webb DJ, Monge JC, Rabelink TJ, et al. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 1998;19:5-8.
15. Brown CD, Barnes K, Turner AJ. Functional significance of the isoforms of endothelin-converting enzyme-1. J Cardiovasc Pharmacol. 2000;36(suppl 1): S26-S27.
16. Jasmin JF, Dupuis J. Evaluation of luminal endothelin-converting enzyme activity in the pulmonary and coronary circulations. J Cardiovasc Pharmacol. 2004;43:21-25.
17. Seyrantepe V, Hinek A, Peng J, et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation. 2008;117:1973-1981.
18. Abassi ZA, Tate JE, Golomb E, et al. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 1992;20:89-95.
19. Tran Duc AT, Schwab AJ, Simard A, et al. Reduction in hepatic endothelin-1 clearance in cirrhosis. Clin Sci. 2003;105:227-234.
20. Dupuis J, Goresky CA, Rose CP, et al. Endothelin-1 myocardial clearance, production, and effect on capillary permeability in vivo. Am J Physiol. 1997;273(3 pt 2):H1239-H1245.
21. Johnström P, Fryer TD, Richards HK, et al. In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET). Br J Pharmacol. 2005;144:115-122.
22. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
23. Papassotiriou J, Morgenthaler NG, Struck J, et al. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem. 2006;52:1144-1151.
24. Khan SQ, Dhillon O, Struck J, et al. C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J. 2007;154:736-742.
25. Levin ER. Mechanisms of disease: endothelins. N Engl J Med. 1995;333: 356-363.
26. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol. 1999;126:391-398.
27. Tamirisa P, Frishman WH, Kumar A. Endothelin and endothelin antagonists. Roles in cardiovascular health and disease. Am Heart J. 1995; 130:601-610.
28. Gray G, Webb D. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther. 1996;72:109-148.
29. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelial receptor. Nature. 1990;348:730-732.
30. Lin HY, Kaji EH, Winkel GK, et al. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci USA. 1991;88:3185-189.
31. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of the endothelin receptors. Trends Pharmacol Sci. 1992;13:103-108.
32. Kaur S, Frishman WH, Singh I, et al. Endothelin as a therapeutic target in the treatment of cardiovascular disease. Heart Dis. 2001;3:176-188.
33. Davenport AP. International union of pharmacology, XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002;54:219-226.
34. Masaki T, Ninomiya H, Sakamoto A, et al. Structural basis of the function of endothelin receptor. Mol Cell Biochem. 1999;61:391-415.
35. Hosoda K, Nakao K, Hiroshi-Arai, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. 1991;287:23-26.
36. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993;72:526-538.
37. Spatz M, Kawai N, Merkel N, et al. Functional properties of cultured endothelial cells derived from large microvessels of human brain. Am J Physiol. 1997;272(1 pt 1):C231-C239.
38. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
39. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10:1379-1386.
40. Masaki T, Kimura S, Yanagisawa M, et al. Molecular and cellular mechanism of endothelin regulation: implications for vascular function. Circulation. 1991; 84:1457-1468.
41. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA. 1989;86:3915-3918.
42. Inoue Y, Oike M, Nakao K, et al. Endothelin augments unitary calcium channel currents on the smooth muscle cell membrane of guinea-pig portal vein. J Physiol. 1990;423:171-191.
43. 2+-permeable nonselective cation channel in endothelin-1-induced contraction of rabbit aorta. J Cardiovasc Pharmacol. 1997;30:504-509.
44. Turner NC, Dollery CT, Williams AJ. Endothelin-1-induced contractions of vascular and tracheal smooth muscle: effects of nicardipine and BRL 34915. J Cardiovasc Pharmacol. 1989;13(suppl 5):S180-S182.
45. 2+ influx. Eur J Pharmacol. 1996;409:644-646.
46. Miwa S, Kawanabe Y, Okamoto Y, et al. Ca2+ entry channels involved in endothelin-1-induced contractions of vascular smooth muscle cells. J Smooth Muscle Res. 2005;41:61-75.
47. Miller RC, Pelton JT, Huggins JP. Endothelins-from receptors to medicine. Trends Pharmacol Sci. 1993;14:54-60.
48. Bell RM, Hannun YA, Loomis CR. Mechanism of regulation of protein kinase C by lipid second messengers. Symp Fundam Cancer Res. 1986; 39:145-156.
49. Krämer BK, Smith TW, Kelly RA. Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. Circ Res. 1991;68:269-279.
50. Wang H, Sakurai K, Endoh M. Pharmacological analysis by HOE642 and KB-R9032 of the role of Na+/H+ exchange in the endothelin-1-induced Ca2 signaling in rabbit ventricular myocytes. Br J Pharmacol. 2000;131:638-644.
51. Trevisi L, Bova S, Cargnelli G, et al. Endothelin-1-induced arachidonic acid release by cytosolic phospholipase A2 activation in rat vascular smooth muscle via extracellular signal-regulated kinases pathway. Biochem Pharmacol. 2002;64:425-431.
52. Mitchell JA, Ali F, Bailey L, et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol. 2008;93:141-147.
53. Scotland RS, Madhani M, Chauhan S. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005;111:796-803.
54. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol. 2006;25:1215-1225.
55. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133-138.
56. Battistini B, Berthiaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood). 2006;231:653-695.
57. Tamirisa P, Frishman WH, Kumar A. Endothelins and endothelin antagonism. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw Hill; 1997:697.
58. Kirby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol. 2007;153:1105-1119.
59. Luscher TF, Barton M. Endothelin and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
60. Spieker LE, Noll G, Ruschitzka FT, et al. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 2001;37:1493-1505.
61. Davenport AP, O'Reilly G, Kuo RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995;114:1110-1116.
62. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol. 1995;35:235-255.
63. D'Orleans-Juste P, Labonte J, Bkaily G, et al. Function of the endothelin B receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther. 2002;95:221-238.
64. Quaschning T, Voss F, Relle K, et al. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol. 2007;18:730-740.
65. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
66. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860-1870.
67. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752-756.
68. Gariepy CE, Ohuchi T, Williams SC, et al. Salt-sensitive hypertension in endothelin-B receptor deficient rats. J Clin Invest. 2000;105:925-933.
69. Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted over-expression of human endothelin-1 causes vascular remodeling and endothelial cell dysfunction. Circulation. 2004;110:2233-2240.
70. Ahn D, Ge Y, Stricklett P, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004;114:504-511.
71. Bagnall AJ, Kelland NF, Gulliver-Sloan F, et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension. 2006;48:286-293.
72. Ge Y, Bagnall A, Stricklett P, et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol. 2006;291:F1274-F1280.
73. Brunner F, Brás-Silva C, Cerdeira AS, et al. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther. 2006; 111:508-531.
74. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
75. Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol. 1996;27:643-651.
76. Schiffrin EL, Lariviere R, Li JS, et al. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res. 1996;33:235-248.
77. Hirai Y, Adachi H, Fujiura Y, et al. Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: an epidemiological study. J Hypertens. 2004;22:713-718.
78. Tomobe Y, Miyauchi T, Saito A, et al. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats. Eur J Pharmacol. 1988;l52:373-374.
79. Ergul S, Parish DC, Puett D, et al. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28:652-655.
80. Campia U, Cardillo C, Panza JA. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation. 2004;109:3191-3195.
81. Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753-758.
82. Noll G, Wenzel RR, Schneider M, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation. 1996;93:866-869.
83. Miyauchi T, Yanagisawa M, Iida K, et al. Age and sex related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J. 1992;123:1092-1093.
84. Sturrock ND, Lang CC, MacFarlane LJ, et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens. 1995;13:667-673.
85. Phillips PA, Rolls KA, Burrell LM, et al. Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertension. Clin Exp Pharmacol Physiol. 1994;21:223-226.
86. Bartholomeusz B, Hardy KJ, Nelson AS, et al. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension. 1996;27:1341-1345.
87. Lteif A, Vaishnava P, Baron AD, Mather1 KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007;56:728-734.
88. Ahlborg G, Shemyakin A, B̈ Ohm F, et al. Dual Endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care. 2007;30:591-596.
89. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002;106:1919-1924.
90. Correia ML, Morgan DA, Sivitz WI, et al. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 2001;37:936-942.
91. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052-3056.
92. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension. 1999;34:1047-1052.
93. Toth MJ, Gottlieb SS, Fisher ML, et al. Plasma leptin concentrations and energy expenditure in heart failure patients. Metabolism. 1997;46:450-453.
94. Juan C-C, Chuang T-Y, Lien C-C, et al. Leptin increases endothelin type A receptor levels in vascular smooth muscle cells. Am J Physiol Endocrinol Metab. 2008;294: E481-E487.
95. Xu F-P, Chen M-S, Wang Y-Z, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004;110:1269-1275.
96. Phillipsa BG, Narkiewiczb K, Pesekb CA, et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999;17:61-66.
97. Kanagy NL, Walker BR, Nelin LD. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension. 2001;37:511-515.
98. Allahdadi KJ, Walker BR, Kanagy NL. Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension. 2005; 45:705-709.
99. Gjørup PH, Sadauskiene L, Wessels J, et al. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens. 2007;20:44-52.
100. Belaidi E, Joyeux-Faure M, Ribuot C, et al. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol. 2009;53:1309-1317
101. Sudo N, Kamoi K, Ishibashi M, et al. Plasma endothelin-1 and big endothelin-1 levels in women with pre-eclampsia. Acta Endocrinol (Copenh). 1993;129:114-120.
102. Lamarca BD, Ryan MJ, Glibert JS, et al. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9:480-485.
103. Mastrogiannis DS, O'Brien WF, Krammer J, et al. Potential role of endothelin-1 in normal and hypertensive pregnancies. Am J Obstet Gynecol. 1991;165(6 pt 1):1711-1716.
104. Saǧsöz N, Küçüközkan T. The effect of treatment on endothelin-1 concentration and mean arterial pressure in preeclampsia and eclampsia. Hypertens Pregnancy. 2003;22:185-191.
105. Cervar M, Puerstner P, Kainer F, et al. Endothelin-1 stimulates the proliferation and invasion of first trimester trophoblastic cells in vitro-a possible role in the etiology of preeclampsia? J Invest Med. 1996;44:447-453.
106. Takahashi K, Totsune K, Mori T. Endothelin in chronic renal failure. Nephron. 1994;66:373-379.
107. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens. 1993;6:103-107.
108. Oishi S, Sasaki M, Sato T. Elevated immunoreactive endothelin levels in patients with pheochromocytoma. Am J Hypertens. 1994;7:717-722.
109. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol. 2007;50:621-628.
110. Li LX, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelinA-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058.
111. Callera GE, Touyz RM, Teixeira SA, et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension. 2003;42:811-817.
112. Dohi Y, Hahn AWA, Boulanger CM, et al. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19:131-137.
113. Sung CP, Arleth AJ, Storer BL, et al. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin bisynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 1994;271:429-437.
114. d'Uscio LV, Shaw S, Barton M, et al. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension. 1998;31:1305-1310.
115. Ortiz MC, Manriquez MC, Romero JC, et al. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension. 2001;38: 655-659.
116. Powell JS, Clozel JP, Muller RK, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
117. Moreau P, d'Uscio LV, Shaw S, et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96:1593-1597.
118. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats. Effect of endothelin ETA receptor antagonism. Circulation. 2001;103:319-324.
119. Bayerel-Eder M, Langenberger H, Pleiner J, et al. Endothelin ETA receptorsubtype specific antagonism does not mitigate the acute systemic or renal effects of exogenous angiotensin II in humans. Eur J Clin Invest. 2002;32:230-235.
120. Montanari A, Biggi A, Carra N, et al. Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans. Hypertension. 2003;42:825-830.
121. Donckier JE, Massart PE, Hodeige D, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensinconverting enzyme inhibition. Circulation. 1997;96:1250-1256.
122. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338:784-790.
123. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15:583-589.
124. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, doubleblind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007;9:760-769.
125. Darusentan meets goals of late-stage hypertension trial. Thought Leader Connect Cardiology Edition. April 16, 2009.
126. Motte S, McEntee K, Naejie R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110:386-414.
127. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23:1441-1444.
128. Massart PE, Hodeige DG, Mechelen HV, et al. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine hypertension. J Hypertens. 1998;16:835-841.
129. Bohlender J, Gerbaulet S, Kramer J, et al. Synergistic effects of AT1 and ETA receptor blockade in a transgenic, angiotensin II-dependent rat model. Hypertension. 2000;35:992-997.
130. Dhein S, Hochreuther S, Aus Dem Spring C, et al. Long-term effects of the endothelin (A) receptor antagonist LU 135252 and the angiotensin converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type 1 diabetes mellitus rat model. J Pharmacol Exp Ther. 2000;293:351-359.
131. Dascal D, Nirula V, Lawus K, et al. Shared determinants of receptor binding for subtype selective and dual endothelin-angiotensin antagonists on the AT1 angiotensin II receptor. FEBS Lett. 1998;423:15-18.
132. Murugesan N, Tellew JE, Gu Z, et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem. 2002;45:3829-3835.
133. Murugesan N, Gu Z, Spergel S, et al. Biphenylsulfonamide endothelin receptor antagonists. Discovery of N-[[2′-[(4,5-dimethyl-3-isoxazolyl) amino[sulfonyl]-4-(2-oxazolyl)]1,1′-biphenyl]-2-]methyl]-N3, 3-timethylbutanamide (BMS-207 940), a highly potent and orally active ETA selective antagonist. J Med Chem. 2003;46:125-137.
134. Murugesan N, Gu Z, Fadnis L, et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2′-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005;48:171-179.
135. Neutal JM. Meeting highlights: American Society of hypertension. Pharm Ther. 2008;33:479.
136. Morrell NW, Upton PD, Higham MA, et al. Angiotensin II stimulates proliferation of human pulmonary artery smooth muscle cells via the AT1 receptor. Chest. 1998;114:90S-91S.
137. Kishi K, Jin D, Takai S, et al. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res. 2006;60:77-82.
138. Zhao X, Li X, Trusa S, et al. Angiotensin type 1 receptor is linked to inhibition of nitric oxide production in pulmonary endothelial cells. Reg Peptides. 2005;132:113-122.
139. Lefebvre F, Préfontaine A, Calderone A, et al. Modification of the pulmonary renin-angiotensin system and lung structural remodeling in congestive heart failure. Clin Sci. 2006;111:217-224.